Loading clinical trials...
Loading clinical trials...
SMT C1100 - A Phase 1b, Open-label, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Paediatric Patients With Duchenne Muscular Dystrophy
Conditions
Interventions
SMT C1100
Locations
4
United Kingdom
Heart of England NHS Foundation Trust - Heart Lands Hospital
Birmingham, United Kingdom
Alder Hey Children's NHS Foundation Trust
Liverpool, United Kingdom
Great Ormond Street for Children NHS Foundation Trust
London, United Kingdom
Central Manchester University Hospitals NHS Foundation Trust- Royal Manchester Children's Hospital
Manchester, United Kingdom
Start Date
November 1, 2013
Primary Completion Date
May 1, 2014
Completion Date
July 1, 2014
Last Updated
August 27, 2014
NCT07037862
NCT07160634
NCT06450639
NCT07129954
NCT06290713
NCT06925269
Lead Sponsor
Summit Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions